Aerie's Roclatan meets in second Phase III for IOP

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) reported top-line data from the Phase III Mercury 2 trial in 750 patients with open-angle glaucoma or ocular hypertension with a baseline intraocular pressure (IOP) of >20 to <36 mmHg showing that

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.